Study

Overview

Official Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer’s disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person’s ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: • If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD & damages brain cells. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment. • About the safety of MK-2214 and if people tolerate it

Study Type:

Interventional

Study Phase:

Phase 2

Estimated Enrollment:

340

Study Start Date:

July 2025

Estimated Study Completion Date:

April 2029

Estimated Primary Completion Date:

April 2029

Eligibility

Ages Eligible for Study:

50 years to 85 years

Genders Eligible for Study:

All

Accepts Healthy Volunteers:

No

CRITERIA

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD)
Has a designated study partner who can fulfill the requirements of this study
If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

Has a known history of stroke or cerebrovascular disease
Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
Has structural brain disease
Has a history of seizures or epilepsy within 5 years before screening
Has any other major central nervous system trauma, or infections that affect brain function
Has major medical illness or unstable medical condition within 3 months before screening
Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study
Has a bleeding disorder that is not under adequate control
Has a history of malignancy occurring within 5 years of screening
Has a risk factor for corrected QT interval (QTc) prolongation
Has liver disease
Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision

Locations

United States Toll Free Number 1-800-770-4674

Inglewood, California, 90301
Irvine, California, 92614
Long Beach, California, 90804
Redlands, California, 92374
San Francisco, California, 94158
Santa Ana, California, 92705
Atlantis, Florida, 33462
Fort Myers, Florida, 33912
Maitland, Florida, 32750
Melbourne, Florida, 32940
Naples, Florida, 34105
New Port Richey, Florida, 34652
Ocala, Florida, 34471
Orlando, Florida, 32803
Tampa, Florida, 33607
Tampa, Florida, 33609
Winter Park, Florida, 32789
Decatur, Georgia, 30030
Elk Grove Village, Illinois, 60007
Newton, Massachusetts, 02459
Springfield, New Jersey, 07081
Toms River, New Jersey, 08755
Albany, New York, 12208
Plymouth Meeting, Pennsylvania, 19462
Beaumont, Texas, 77702

Results

No Study Results Posted

Study Detail

A Clinical Study of MK-2214 in People with Early Alzheimer’s Disease (MK-2214-004)

Overview

Eligibility

CRITERIA

Locations

Results